Welcome to our dedicated page for Accenture Plc Ireland SEC filings (Ticker: ACN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Accenture plc (ACN) SEC filings page brings together the company’s official disclosures to the U.S. Securities and Exchange Commission, including annual and quarterly financial reports, proxy materials and current reports on significant events. As a New York Stock Exchange‑listed company incorporated in Ireland, Accenture uses these filings to provide detailed information on its financial performance, governance, strategy and material developments.
Accenture’s Form 8‑K current reports frequently furnish earnings releases for quarterly and annual periods, outlining revenues, operating margin, earnings per share, bookings, free cash flow and other key metrics. These 8‑K filings also describe the company’s use of non‑GAAP measures such as free cash flow, local‑currency growth and adjusted results that exclude specified business optimization costs, along with reconciliations to GAAP figures. Other 8‑K filings disclose leadership and organizational changes, including updates to Accenture’s growth model and senior management roles.
The company’s definitive proxy statement (DEF 14A) provides extensive detail on corporate governance, board structure, director nominees, executive compensation programs, share incentive plans and shareholder proposals. It also discusses Accenture’s strategy to be the reinvention partner of choice for clients, its Reinvention Services structure, and multi‑year trends in revenue growth, margins, earnings and cash returned to shareholders.
Through this page, users can access Accenture’s 10‑K annual reports, 10‑Q quarterly reports, 8‑K current reports, proxy statements and related exhibits as they are filed with the SEC’s EDGAR system. Stock Titan enhances these documents with AI‑powered summaries that highlight the main points of lengthy filings, explain non‑GAAP reconciliations, and surface items such as compensation plans and governance proposals. Investors tracking ACN can use these filings to review historical performance, understand management’s reporting practices and monitor material events affecting the company.
Paula A. Price, a director of Accenture plc (ACN), was granted 7,361 Class A ordinary shares as Restricted Share Units (RSUs) on 08/15/2025 at an indicated price of $247.57 per share. The Form 4 reports the acquisition code "A" and explains these RSUs were issued pursuant to anti-dilution provisions of previously granted awards to reflect Accenture's cash dividend. After the grant, Ms. Price beneficially owns 7,361 shares in direct form. The filing was signed by an attorney-in-fact on 08/18/2025.
Accenture plc (ACN): Director Venkata S. M. Renduchintala reported a Section 16 transaction dated 08/15/2025 showing acquisition of 3,703 Class A ordinary shares. The Form 4 indicates the shares were granted as Restricted Share Units (RSUs) under anti-dilution provisions tied to a cash dividend and lists a price of $247.57. The filing shows the shares are held directly and was signed on behalf of the reporting person by an attorney-in-fact on 08/18/2025.
Arun Sarin, a director of Accenture plc (ticker ACN), reported an acquisition on 08/15/2025 of 8,473 Class A ordinary shares via grant (Transaction Code A) of restricted share units. The grant was made pursuant to anti-dilution provisions tied to previously awarded RSUs to reflect Accenture's payment of a cash dividend. The reported price per share is $247.57, and the amount beneficially owned following the transaction is listed as 8,473 shares. The Form 4 was signed on behalf of Mr. Sarin by an attorney-in-fact on 08/18/2025.
Accenture plc (ACN) director Tracey Thomas received a grant of restricted share units (RSUs) tied to prior awards to reflect a cash dividend. The Form 4 shows a transaction dated 08/15/2025 recorded as an acquisition (code A) with a reference price of $247.57. Following the reported transaction the filing lists 8,573 Class A ordinary shares beneficially owned. The filing was signed on behalf of Tracey Thomas by an attorney-in-fact on 08/18/2025. The explanatory note states the grant resulted from anti-dilution provisions of previously granted RSU awards to reflect Accenture's dividend payment.
Masahiko Uotani, a director of Accenture plc (ACN), received a grant of 619 Class A ordinary shares recorded as restricted share units (RSUs) on 08/15/2025. The Form 4 reports the shares were issued pursuant to anti-dilution provisions tied to previously granted RSU awards to reflect Accenture's cash dividend. The reported transaction lists a price of $247.57 and shows 619 shares beneficially owned following the grant in a direct ownership form. The filing was signed by an attorney-in-fact on 08/18/2025. No other transactions, derivative holdings, or additional compensation details are disclosed in this Form 4.
Accenture plc (ACN) Form 4: Atsushi Egawa, listed as Co-CEO Asia Pacific and an officer of Accenture, reported a transaction dated 08/15/2025. The filing shows a grant of restricted share units (RSUs) issued pursuant to anti-dilution provisions tied to previously granted RSU awards to reflect Accenture's cash dividend. The reported transaction lists Class A ordinary shares related to the RSU grant and indicates an acquisition event. The form was signed by an attorney-in-fact on 08/18/2025. The filing discloses direct and indirect holdings, including shares held by an immediate family member.
Insider transaction at Accenture plc (ACN): Angie Y. Park, listed as Chief Financial Officer and reporting person, acquired restricted share units on 08/15/2025 under a grant described as anti-dilution adjustments related to Accenture's cash dividend. The Form 4 reports a transaction coded "A" with a price shown as $247.57 and a reported post-transaction beneficial ownership of 7,762 Class A ordinary shares. The filing is signed by an attorney-in-fact on 08/18/2025.
Manish Sharma, an officer (CEO-The Americas) of Accenture plc (ACN), reported a change in beneficial ownership on Form 4. On 08/15/2025 the filing records a non-derivative transaction tied to Class A ordinary shares showing a price of $247.57 and a reported transaction code indicating acquisition under an award. The explanatory note states these were Restricted Share Units (RSUs) granted pursuant to anti-dilution provisions of previously granted RSU awards to reflect Accenture's payment of a cash dividend. Following the reported transaction(s), the filing shows 1,740 shares beneficially owned in a direct ownership form. The Form 4 was signed by an attorney-in-fact on 08/18/2025.
Julie Spellman Sweet, Chair and CEO of Accenture plc (ACN), received restricted share units (RSUs) on 08/15/2025 as recorded on this Form 4. The filing shows an acquisition coded as "A" related to anti-dilution adjustments for previously granted RSU awards to reflect Accenture's cash dividend. The reported transaction lists a unit price of $247.57 and indicates 8,288 Class A ordinary shares beneficially owned following the transaction. The Form 4 is signed by an attorney-in-fact on behalf of Ms. Sweet on 08/18/2025.
Insider grant recorded for Accenture plc (ACN) — John F. Walsh, listed as Chief Operating Officer and reporting person, reported a transaction dated 08/15/2025 showing restricted share units granted under anti-dilution provisions tied to a cash dividend. The Form 4 reports 16,190 Class A ordinary shares as the amount of securities beneficially owned following the reported transaction. The filing is signed by an attorney-in-fact on behalf of Mr. Walsh and notes the grant was a mechanical adjustment to prior RSU awards to reflect Accenture’s dividend payment.